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Abstract
Background:  The spread of drug resistance is making malaria control increasingly difficult.
Mathematical models for the transmission dynamics of drug sensitive and resistant strains can be a
useful tool to help to understand the factors that influence the spread of drug resistance, and they
can therefore help in the design of rational strategies for the control of drug resistance.
Methods: We present an epidemiological framework to investigate the spread of anti-malarial
resistance. Several mathematical models, based on the familiar Macdonald-Ross model of malaria
transmission, enable us to examine the processes and parameters that are critical in determining
the spread of resistance.
Results: In our simplest model, resistance does not spread if the fraction of infected individuals
treated is less than a threshold value; if drug treatment exceeds this threshold, resistance will
eventually become fixed in the population. The threshold value is determined only by the rates of
infection and the infectious periods of resistant and sensitive parasites in untreated and treated
hosts, whereas the intensity of transmission has no influence on the threshold value. In more
complex models, where hosts can be infected by multiple parasite strains or where treatment
varies spatially, resistance is generally not fixed, but rather some level of sensitivity is often
maintained in the population.
Conclusions:  The models developed in this paper are a first step in understanding the
epidemiology of anti-malarial resistance and evaluating strategies to reduce the spread of
resistance. However, specific recommendations for the management of resistance need to wait
until we have more data on the critical parameters underlying the spread of resistance: drug use,
spatial variability of treatment and parasite migration among areas, and perhaps most importantly,
cost of resistance.
Background
The treatment of malaria infections and the control of the
spread of malaria are made increasingly difficult by drug
resistant strains of the parasite. Resistance to chloroquine,
an effective and safe anti-malarial that formed the first
line of treatment, emerged more than 30 years ago [1],
and since then malaria parasites have developed resist-
ance against most of the widely used anti-malarials, in-
cluding sulfadoxine-pyrimethamine [2,3], mefloquine [4]
and quinine [5]. Indeed, it is now generally believed that
the widespread use of a new drug will inevitably be fol-
lowed by the appearance of resistance in the parasite pop-
ulation. There is, therefore, increasing emphasis in
malaria control on rational management of drug use in an
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attempt, if not to prevent, then at least to delay the spread
of resistance in the parasite population. One approach is
to use combination therapy, where the simultaneous use
of several drugs is hoped to delay the emergence of resist-
ance [6,7]. Another approach could be to use drugs in a
mosaic fashion (temporally or spatially), so that resist-
ance to individual drugs is counter-selected where or
when the drug is not used, as is discussed for the manage-
ment of antibiotic resistance [8]. However, predicting the
effect of different strategies for drug use on the spread of
resistance to the drug is not straightforward because of the
complex interactions that determine the transmission of
the parasite between human and mosquito populations.
Mathematical models have in the past provided a valuable
framework for analysing the transmission dynamics of
malaria [9,10]. These models have been widely used to
consider the effect of different strategies such as vector
control [11] and the use of future vaccines on the trans-
mission dynamics of malaria [12,13].
In this paper, we extend these models to investigate the
spread of drug resistance in malaria. We develop models
of malaria transmission that allow us to examine the sim-
plest case: the spread of resistance to a single drug, encod-
ed at a single genetic locus. We modify standard
epidemiological models of malaria transmission to incor-
porate drug sensitive and drug resistant parasite popula-
tions, and use this model to investigate the conditions
under which drug resistance will spread in the population
of hosts, as well as to predict the rate of spread of resist-
ance. We then examine how superinfection or heterogene-
ity in treatment will modify the earlier results.
Our epidemiological models provide a counterweight to
the recent models based on population genetic considera-
tions [14–16]. One of the purposes of the paper is thus to
discuss the similarities and differences in the predictions
of the genetic and epidemiological models. But our main
aims are to find which parameters would be necessary to
predict the spread of resistance and to emphasize our lack
of knowledge about any of these parameters.
Models
Epidemiological framework
Our models are based on previously published extensions
of the classical Macdonald-Ross model, which take into
account acquired immunity by humans and allow the du-
ration of immunity to depend on exposure (i.e. that im-
munity is boosted by additional infections) [17,18].
Though the assumptions about the development of im-
munity are undoubtedly overly simple, the model can
predict several important epidemiological patterns, e.g.
that the crude prevalence of malaria in a population may
decrease at very high levels of transmission [19,20]. Fur-
thermore, variations of the model (where immunity is
life-long or where the duration of immunity is constant,
rather than being boosted by new infections) gave similar
predictions, so that our results are robust with respect to
details of the dynamics of immunity.
The human population is split into a proportion x of sus-
ceptibles, a proportion y of infecteds and a proportion z of
immunes (Fig. 1). The changes in the proportions of these
three categories are described by three differential
equations:
Susceptibles become infected at the inoculation rate h
(which is derived below). Infected individuals recover at a
rate r to become immune, and immunes loose their im-
munity and become susceptible again at a rate ρ. Deaths
occur at a rate δ (i.e. the life-expectancy is 1/δ) and are not
affected by disease status. Deaths are balanced by births
into the susceptible class, so that the population size re-
mains constant.
If the duration of immunity is ω years in the absence of
new infections and immunity is boosted by re-exposure,
Figure 1
Schematic illustration of the basic malaria model. As dis-
cussed more fully in the text, the diagram shows the catego-
ries of host and vector individuals considered in the model, 
the transitions between the categories and the transmission 
processes.
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reference [20] shows that the rate at which immunity is
lost can be set to
Consider next the infection rate of mosquitoes. The mos-
quito population is split into three categories: a propor-
tion v of infected mosquitoes that have not yet developed
infectious sporozoites, a proportion w of infectious indi-
viduals with sporozoites in the salivary glands, and a pro-
portion 1 - v - w of uninfecteds. Susceptible mosquitoes
become infected by biting infected humans at a rate a;
only a proportion b of the bites lead to infection. Thus the
proportion of infected mosquitoes increases at a rate
aby(1 - v - w). The newly infected mosquitoes become in-
fectious to humans, if they survive the incubation period,
τ, required for the development of the parasite. Assuming
a mortality rate µ, a proportion e-µT survives this period.
Thus, of the aby(1 - v - w) mosquitoes infected τ days ear-
lier, aby(1 - v - w)e-µT move from the latent to the infec-
tious state. The proportions of latent and infectious
mosquitoes decrease through mortality. The process of in-
fection can thus be summarized as
where ,   and  .
Because the mosquito dynamics operate on a much faster
time-scale than the human dynamics described by equa-
tion (1), the mosquito population can be considered to be
at equilibrium with respect to changes in the human pop-
ulation. This allows its dynamics to be collapsed into the
inoculation rate h:
where m denotes the number of mosquitoes per human.
As is customary for epidemiological models, transmission
is summarized by the basic reproductive number, which
gives the number of secondary cases following introduc-
tion of a single infected individual into a susceptible
population.
As an indicator of the intensity of transmission, Ro will
tend to be increased by natural selection, and parasites
with higher Ro will invade populations of parasites with
lower reproductive numbers.
Spread of resistance
The basic model can easily be extended to describe the
spread of resistant parasites. We assume that resistance is
conferred by an allele at one locus, so that we can consider
the spread of resistance as competition among two strains
of parasites, an anti-malarial sensitive and a resistant one.
We further assume that a fraction f of the infected individ-
uals is treated. With these assumptions, the compartment
model of Figure 1 is changed to allow for three sub-com-
partments of infected individuals: hosts that are infected
with the sensitive strain but that are not treated, hosts in-
fected with the sensitive strain and treated, and hosts in-
fected with the resistant strain, which is not affected by
treatment (Fig. 2). With the subscripts S and R denoting
sensitive and resistant strains, respectively, and the sub-
scripts U and T denoting untreated and treated infections,
equations (1) are modified to
The inoculation rates of sensitive and resistant parasites
can be calculated as
where yS = yST + ySU. The inoculation rate of the resistant
parasites can be written as
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where   is the change of transmission due to a
change from sensitivity to resistance; it denotes the trans-
mission cost of resistance. Note that, although we have
modelled the transmission cost in terms of infectivity
from the human to the mosquito, the cost can also be ex-
pressed in terms of other transmission parameters. Mos-
quitoes harbouring resistant parasites, for example, may
bite less frequently or experience higher mortality than
those infected with sensitive parasites.
We further assume that the differences in recovery rate are
due to treatment and to a cost of resistance within the hu-
man host. Therefore
rSU <rR <rST   (9)
We can estimate the relative transmission of the sensitive
and resistant parasites with their basic reproductive num-
bers. Letting equation (5) denote the basic reproductive
number of the untreated, sensitive parasites and assuming
that the average life-span of humans is considerably great-
er than the duration of infection (1/δ >> 1/rSU), the basic
reproductive number of the sensitive parasites (in the ab-
sence of resistant ones) becomes
where Ro equals the basic reproductive number defined in
equation (5), i.e. for sensitive parasites in the absence of
treatment. The basic reproductive number of the sensitive
infections declines linearly with increasing treatment. In
the absence of resistance treatment can eradicate the dis-
ease, if it drives the basic reproductive number to less than
unity, i.e. if the fraction of infections treated is larger than
a critical value fe given by:
If we introduce resistant parasites, the outcome depends
on the relative magnitude of the basic reproductive num-
bers of the sensitive and resistant infections. The latter is
given by
where Γ = γt rR/rSU describes the reduction of the intensity
of transmission due to a switch from sensitivity to resist-
ance and can therefore be defined as the total cost of re-
sistance. The long-term outcome will depend on whether
RR is larger than RS, which in turn depends on whether the
proportion of individuals receiving treatment exceeds a
threshold fc defined as
If the proportion of treated individuals is less than the
threshold fc, RS >RR and all parasites in the population re-
main sensitive. If the proportion of treated individuals is
higher than fc, all parasites will eventually become
resistant. Note that this proportion depends only on two
parameters: the cost of resistance and the ratio of the peri-
ods of infection in treated and untreated individuals. In
particular, the threshold proportion is independent of the
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Figure 2
Modification of the illustration shown in Fig. 1 to incorporate 
resistant and sensitive parasites. The infected humans are 
split into 3 categories, representing untreated-sensitive, 
treated-sensitive, and resistant infections. The mosquitoes 
are split into two cohorts, representing sensitive and resist-
ant infections.
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intensity of transmission (measured as Ro, the basic repro-
ductive number of the sensitive strain in the absence of
treatment). Similarly, the rate at which resistance spreads,
once the threshold proportion of treatment is exceeded,
depends largely on the frequency of treatment and the
cost of treatment, but is almost independent of the inten-
sity of transmission (Fig. 3).
Thus, in this model, there is competitive exclusion be-
tween resistant and sensitive parasites. Whether sensitivity
or resistance predominates in the population depends on
three parameters: (i) the proportion of infected individu-
als that receive treatment, (ii) the effectiveness of treat-
ment defined in terms of period of infection as ε = 1 - rSU/
rST, and (iii) the cost of resistance.
Superinfection of hosts
In the previous model we assumed that hosts cannot be
superinfected by a second parasite, which would lead to
mixture of sensitive and resistant parasites in the same pa-
tient. In this section we relax this assumption and allow
superinfection of hosts, assuming that sensitive and resist-
ant parasites develop independently within their host. We
further assume that the treatment has a short half-life, so
that the decision to treat superinfections is independent of
any earlier treatment. In other words, a proportion f of all
superinfections will be treated, while a proportion 1 - f
will not be treated, irrespective of whether the first infec-
tion was treated or not. (We also analyzed a model where
the treatment has a long-life and where the superinfecting
parasite therefore receives the same treatment as the first
infection. In this case, treated individuals cannot be super-
infected with a sensitive parasite. The conclusions are the
same as the ones reached with the equations given here).
With these assumptions equations (6) can be modified to
where the subscript M denotes mixed infections. The inoc-
ulation rates of sensitive and resistant parasites are
changed accordingly as
where yS = yST + ySU and yM = yMT + yMU.
With this model the parasite population switches from be-
ing predominantly sensitive to being predominantly re-
sistant at a similar frequency as in the model without
superinfection (defined by equation 13). The main differ-
ence due to superinfection is that competitive exclusion is
not always achieved. At intermediate levels of treatment
resistant and sensitive parasites can coexist in the same
population (Fig. 4). The area where coexistence is possible
increases as the cost of resistance decreases. Furthermore,
if the cost is sufficiently low, resistance can invade a sensi-
tive population even when there is no treatment, so that
Figure 3
Time in years for resistant parasites to reach a frequency of 
50% as a function of the level of treatment, f, and the basic 
reproductive number of untreated-sensitive infections, Ro. 
Equations (6) and (7) were integrated with only sensitive par-
asites until an equilibrium was reached. Then a resistant par-
asites were introduced at a frequency of 10-4 and the 
equations were integrated until the frequency of resistance 
reached 50%. The parameters used to integrate the equa-
tions were: δ = 0.01 year-1, µ = 36.5 year-1 (ca. 0.1 day-1), τ = 
0.03 years (ca. 10 days), a = 100 year-1 (ca. 1/3 day-1), ω = 2 
years, rSU = 1 year-1, rST = 10 year-1 (ca. 1 month-1) and rR = 5 
year-1. The mosquito density m was calculated from equation 
(5) and the given parameters. For these parameters the cost 
of resistance Γ is 5 and the threshold frequency fo is 0.89.
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resistant parasites are found in the absence of any
treatment.
The possibility of coexistence of two parasite strains
comes as no surprise. In many models of epidemiology,
superinfection allows the coexistence of many strains, and
in particular the coexistence of strains with considerable
differences of transmission success [21].
Spatial variability in treatment rates
In this section, we relax a further assumption of the basic
model: that drug treatment is applied uniformly to a pop-
ulation of hosts. In a natural situation, it is more likely
that treatment levels will vary among host individuals and
among host populations. We therefore ask, to what extent
will gene flow via migration counteract the selective forces
due to treatment in a local environment? To do so, we ex-
tend the model defined by equations (6) and (7) by as-
suming that the gene flow is due to migration of the
mosquito vectors infected by sensitive or resistant
parasites.
We will consider two cases. First, following work by
Comins [22] we assume that there is a reservoir of untreat-
ed humans, where all parasites are sensitive. In the treated
area, infection will be due partly to parasites surviving the
treatment in this area and partly to parasites that have mi-
grated from the untreated into the treated area. Second,
we consider several human populations with differing
treatment rates. Infected vectors migrate among neigh-
bouring populations, so that they can migrate from the
treated area to the untreated one.
In the first of these possibilities we assume that the epide-
miology in the untreated area follows the basic model for-
mulated in equations (1)-(4), and that the epidemiology
in the treated area is determined by the competition
between the resistant and the sensitive strains according to
equations (6) and (7). The equations are modified, so that
a proportion m of the infected mosquitoes migrates from
the untreated area to the treated one. In this case the mi-
gration of sensitive parasites into the treated area prevents
the selection of resistance, if the migration rate and the
cost of resistance are high enough (Fig. 5). For lower mi-
gration rates, resistance in the treated area increases to-
wards an intermediate level, which is often close to
fixation. These results are similar to those obtained previ-
ously [22] for the evolution of insecticide resistance.
In the more general case, migration from the treated area
into the untreated zone will not be negligible. We model
this situation by incorporating two areas that are identical
except for their levels of treatment; in one area all infec-
tions are treated, in the other none are. In both, the epide-
miology is modelled according to equations (6) and (7),
and a proportion m (which is independent of area or re-
sistance) of the infected mosquitoes migrates from one
area to the other. At sufficiently low migration rates the
two areas behave independently, with competitive
exclusion within each area; sensitive parasites predomi-
nate in the untreated area (Fig. 6a) and resistant ones pre-
dominate in the treated area (Fig. 6b). At intermediate
migration rates, competitive exclusion between sensitive
and resistant parasites may break down. The level of resist-
ance maintained in either area depends on the combina-
tion of the migration rate and the cost of resistance. A
migration rate of 0.5 corresponds to a well-mixed popula-
tion where half of the infections are treated. If migration
rates exceed this value, the population as a whole is either
completely sensitive or completely resistant; competitive
exclusion operates at the level of the meta-population.
Discussion
Summary of results
Our models enable us to explore the consequences of
changing the level of drug use on the frequency of resist-
ant malaria parasites. In the simplest model, we find a
Figure 4
Spread of resistance in the model that allows superinfection 
of individual hosts by resistant and sensitive parasites. The 
graph shows the proportion of parasites that are resistant 
when the population has reached equilibrium as a function of 
the cost of resistance (defined by equation 12) and the pro-
portion of infections treated. The mosquito density m was 
set to 1, the recovery rate of resistant infections rR was 
determined by the cost of resistance, and the other parame-
ters were as given in Fig. 3.
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threshold level of drug use, below which resistance cannot
spread and above which resistance spreads and eventually
becomes fixed. The threshold level is determined by the
extent to which treatment of sensitive parasites reduces
their duration of infection and by the cost of resistance,
which is defined by the transmissibility of resistant para-
sites and by their duration of infection relative to
untreated infections with sensitive parasites. This compet-
itive exclusion between sensitive and resistant infections
arises, because the parasite with the higher basic reproduc-
tive number Ro drives the number of susceptible hosts be-
low the threshold density that would be necessary to
maintain the parasite with the lower basic reproductive
number [23]. This result is the counterpart to earlier stud-
ies on the spread of resistance in directly transmitted in-
fections [8]. It reflects that resistance is detrimental to the
transmission of the parasite in untreated hosts, but bene-
ficial in treated individuals, so that increasing drug use be-
yond a critical threshold tips the balance from 0% to
100% prevalence of resistance.
Allowing infection of hosts with both types of parasite
gives similar results. The main differences are that, under
some combinations of parameters, the resistant and sensi-
tive parasites can coexist and that, for a low cost of resist-
ance, resistant parasites can coexist with sensitive ones in
the absence of treatment. This reflects the general conclu-
sion that superinfection can maintain several parasite
strains with different basic reproductive numbers [21].
The parasite with low transmission success can infect
hosts that are already infected by the more rapidly
transmitted parasite. Therefore, evolution does not lead to
competitive exclusion and does not maximize transmis-
sion, in contrast to models without superinfection.
Spatial variability in treatment rates can have a larger ef-
fect on the spread of resistance. High migration between
areas with and without treatment can swamp the local ef-
fects of selection. Thus, when the cost of resistance is high,
sensitive parasites can dominate in areas where every host
receives treatment; when the cost of resistance is low, all
parasites in areas where no treatment is available can be-
come resistant. At intermediate costs of resistance and mi-
gration rates, coexistence of sensitive and resistant
parasites is possible within each area. This coexistence
arises as a balance between selection within the popula-
tions and migration between populations. Migrants (with
the inappropriate type) can persist for some time before
they are removed by selection (drug pressure or the cost of
resistance) occurring within each population. Therefore,
at some ratios of migration and selection, both types of
parasites can coexist.
Thus, from the small number of models described here, it
is clear that knowledge about several parameters is critical
for our understanding of the spread of resistance: the drug
use, the spatial variability of treatment and parasite migra-
tion among areas, and perhaps most importantly, the cost
of resistance.
Any data?
Unfortunately, data on any of these parameters are very
limited, and almost completely restricted to chloroquine.
Even data on the use of chloroquine, which may seem to
be the easiest data to get, are poor. Though we may be able
to estimate the total drug use in an area (e.g. 191 tons of
chloroquine in Africa in 1988 [24]), though we may also
obtain the consumption of the drug in an area (e.g. in en-
demic areas, large proportions of children have chloro-
quine residues in their blood at any given time [25]) and
estimate the number of patients with clinical malaria re-
ceiving the drug, the more critical questions are: What
proportion of infected people (as opposed to sick people)
receive treatment, and is the dose of the drug sufficient to
clear the parasites?
Figure 5
Effect of spatial variability in treatment levels on the spread 
of resistance. The model underlying this graph assumes an 
infinite reservoir of untreated individuals (f = 0) and an area 
where all hosts are treated (f = 1), with migration of mosqui-
toes from the untreated to the treated area. The proportion 
of resistant parasites at equilibrium is given as a function of 
the cost of resistance (defined by equation 12) and the pro-
portion of mosquitoes migrating from one area to the other. 
The parameters are as in Fig. 4.
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That resistance, at least against chloroquine, is costly in
terms of transmission is suggested by the observation that
resistance has dropped significantly in several areas when
choloroquine was no longer used. In contrast, however,
some data suggest that resistance is associated with a ben-
efit, rather than a cost, in terms of transmission from hu-
mans to mosquitoes [26–28]. This is supported by in vitro
studies of parasite development showing that resistant
parasites grow more slowly than sensitive parasites, but
develop their transmission stages earlier and at a higher
rate [29]. However, additional factors must balance and
outweigh this apparent benefit of resistance, otherwise re-
sistance would have spread before the wide-spread use of
drugs. The genetic basis for the spread is given. Even be-
fore the use of a drug, resistance is present at low levels in
many populations, in particular for quinine and pro-
guanil [30]. This probably applies for chloroquine as well,
although the data are less convincing [31]). Possible fac-
tors leading to a cost of resistance might be related to the
mortality of infected mosquitoes, since the parasite's
transmission rate is more sensitive to mosquito mortality
than to the effectiveness of transmission from humans to
mosquitoes [9]. Thus, the more effective transmission
from humans to mosquitoes could be more than compen-
sated by the higher mortality of heavily infected mosqui-
toes [32,33]. Overall, there is some qualitative evidence
for a cost of resistance, although quantitative measures of
such a cost are absent.
Critique of the models
Obviously, like other mathematical (or non-mathemati-
cal) models, our equations are simple caricatures of the
epidemiological processes being considered. The success
of a model will depend on the inclusion of the relevant
processes. There are several reasons for believing that the
models we propose capture some aspect of reality. Com-
partment models of infectious diseases in general have
had considerable success in epidemiology [34]. In
particular, compartment models similar to the ones used
here can describe several epidemiological patterns of ma-
laria [11], including, for example, the observation that in-
creased transmission can decrease the malaria prevalence
Figure 6
Effect of spatial variability in treatment levels on the spread of resistance. The model underlying this graph assumes an area of 
untreated individuals (f = 0) and an area where all hosts are treated (f = 1), with migration of mosquitoes between both areas. 
The proportions of resistant parasites at equilibrium in (a) the untreated area and (b) the treated area are given as a function of 
the cost of resistance (defined by equation 12) and the proportion of mosquitoes migrating from one area to the other. The 
parameters are as in Fig. 4.
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among adults of a population [20]. Similar models are
considered helpful in evaluating the sensitivity of malaria
transmission to different control measures [9] and in pre-
dicting the effectiveness of vaccine programmes [13,35].
Compartment models have also been used to examine the
epidemiology of antimicrobial resistance in acute infec-
tions [8] as well as hospital acquired infections [36] and
specific infections such as tuberculosis [37] and HIV [38].
The current paper is a first attempt at applying them to
anti-malarial resistance.
There are a number of specific problems with modelling
the epidemiology of resistance to malaria, which we brief-
ly discuss below. One set of problems concerns the epide-
miological processes of malaria. In this category are
problems associated with the lack of our understanding of
the nature of immunity to malaria at the individual and
epidemiological levels. Thus, the equations describing the
development of immunity reflect the true process only
crudely. However, simulations with two extreme alterna-
tive models (life-long immunity after the first infection or
immunity without boosting, i.e. that is lost at a constant
rate) suggest that our results are insensitive to the details
of the immunological process. Furthermore, we have as-
sumed that treatment does not affect the development of
immunity. While we have no data on this issue for malar-
ia, it is a reasonable assumption that is based on observa-
tions in other systems. The T-cell response to bacteria, for
example, is programmed early in an infection (before the
peak of the inflammatory response) and independent of
the duration and severity of the bacterial infection. In oth-
er words, the infection starts the program, but has little in-
fluence on the further development of the immune
response [39].
A second set of problems is associated with the genetics of
malaria parasites. In this category falls the possibility that
malaria is structured in distinct strains [40,41]. This could
slow the evolution of drug resistance if resistance is due to
several genetic loci [15]. This model and other models
that take into account details of population genetics [14–
16], as have population genetic models of the resistance of
other parasites [34], show the importance and uses of
population genetics. However, just as our equations ne-
glect population genetics, these models have neglected the
epidemiological processes underlying the evolutionary
changes. From our models it appears that the neglect of
epidemiology could qualitatively bias the results; the dif-
ferences between competitive exclusion and coexistence,
for example, can only be reached by explicitly contrasting
different epidemiological assumptions and settings. Per-
haps the best approach would be to merge
epidemiological and genetic models. This approach has
been taken several times in the recent literature with mod-
els taking into account individual infections [42–44], but
it has some major disadvantages. Most importantly, be-
cause of the complexity of the models some important ep-
idemiological features must be omitted. These models
have not (or only in basic terms) taken account of ac-
quired immunity, which is an important aspect of malaria
epidemiology. If merging transmission and genetics is too
complex, it remains to be seen whether focusing on the
genetic side or on the epidemiological side will lead to
better predictions. Certainly, where the genetics are sim-
ple (one locus), the epidemiological approach is more
promising.
Conclusions
The approach offered here can provide insights into sever-
al aspects of the epidemiology of anti-malarial resistance.
It remains unclear why chloroquine resistance has
emerged much later in sub-Saharan Africa than in South-
East Asia [24]. This fact is often attributed to the high
transmission in Africa, with the assumption that high
transmission (and therefore strong acquired and innate
immunity) leads to a slow spread of resistance [31]. This
assumption has indeed been found in some models of the
spread of resistance, because intense transmission is asso-
ciated with less inbreeding, which in turn can lead to
slower spread of resistance under some conditions
[15,16]. However, this prediction is not universal, but de-
pends on the details of the assumptions underlying trans-
mission. Thus our model predicts either little or the
opposite effect of transmission rate, while another recent
model [45] shows that the within-host dynamics of ma-
laria help to determine whether resistance is more likely
to emerge in areas with high or with low transmission. But
perhaps the explanation is much simpler: the use of chlo-
roquine was fairly low until the mid-70s [24], so that re-
sistance would be maintained at a low level due to the cost
of resistance. As the chloroquine consumption increased
to a peak of 191 tons in 1988 [24], it brought a rapid in-
crease of resistance. Unfortunately, we do not have the
quantitative data required to explore this possibility in
more detail.
A further puzzle is that pyrimethamine resistance often
spreads to areas not submitted to pyrimethamine pressure
[46]. One unlikely explanation is that resistance is associ-
ated with a benefit, rather than a cost. Another explana-
tion could be that resistance spreads from areas with high
drug consumption, provided the migration rate is suffi-
ciently high and the cost of resistance is low.
Similarly, there appears to be a low, but non-negligible
level of resistance in most geographical areas even before
exposure to drugs [31]. A possible explanation for this is a
balance between mutation and selection [16], but it might
also be explained by superinfection, which allows resist-Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/3
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ance to be maintained at low levels in areas in the absence
of treatment, if resistance is not too costly.
Overall, an epidemiological approach could lead to valu-
able insights into the spread of resistance. What is needed
is, on the one hand, investigation of the processes deter-
mining the spread and, on the other hand, more detailed
knowledge of the critical parameters involved, e.g. cost of
resistance. Only this will enable us to give advice about ra-
tional drug management that could slow the spread of
resistance.
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